A prescription drug commercial is the most heavily choreographed minute on American television, and everyone knows roughly why: a federal rule forces the risks into the same breath as the benefits. That rule is real, it is written down, and almost none of it reaches the page selling a compounded GLP-1. The gap is not a loophole somebody found. It is the published position of the FDA office that oversees drug promotion, stated on that office’s own consumer page. What not FDA-approved carries for the vial itself is a separate question; this is about what may be said to sell it.
What the rule is for an approved drug
Section 502(n) of the Federal Food, Drug, and Cosmetic Act sets the frame. An advertisement issued by the manufacturer, packer or distributor of a prescription drug must carry the established name printed prominently and in type at least half as large as any brand name, the quantitative formula, and “such other information in brief summary relating to side effects, contraindications, and effectiveness as shall be required in regulations.” Direct-to-consumer print advertisements must carry the MedWatch reporting line verbatim, and a television or radio advertisement that names the drug and its conditions of use must present the major statement on side effects and contraindications “in a clear, conspicuous, and neutral manner.”[1]
The regulation that fills that in, 21 CFR 202.1, is specific to the point of being mechanical. A broadcast advertisement must either contain the brief summary or make “adequate provision… for dissemination of the approved or permitted product labeling.” A television major statement must be in consumer-friendly language, at least as understandable in volume and pacing as the rest of the ad, and presented concurrently using both audio and text, with the text beginning at the same time as the audio and ending at approximately the same time.[2]
Then comes the sentence that explains why none of this transfers. An advertisement is false or misleading, the regulation says, if it contains a representation or suggestion “not approved or permitted for use in the labeling” that a drug is better, more effective, useful in a broader range of conditions or patients, or safer than has been demonstrated by substantial evidence.[2] The test is anchored to approved labeling. A compounded preparation has no approved labeling to be measured against, because nothing was approved.
FDA’s promotion office publishes the boundary itself
The Office of Prescription Drug Promotion describes its mission as helping to ensure that prescription drug promotion is “truthful, balanced, and accurately communicated,” through surveillance, compliance and education.[3] Its consumer-facing Bad Ad page is more specific about scope. It states that OPDP regulates prescription drug promotion “made by or on behalf of the drug’s manufacturer, packer, or distributor,” covering television and radio advertisements, printed promotional materials, internet-based promotion including social media, speaker programs and sales representative presentations.
The same page then lists what OPDP does not regulate the promotion of: over-the-counter drugs, certain biological products, medical devices, foods, drugs for animals, compounded drugs, cosmetics and dietary supplements.[4] That is FDA’s own enumeration, in FDA’s own words, on a page current as of March 6, 2025. Two independent limits produce it: the compounded preparation is not an approved drug with labeling to test claims against, and a telehealth brand that neither manufactures, packs nor distributes the drug is not the party section 502(n) addresses in the first place.
That is a statement about one office’s remit, not a permission, and the paragraphs below set out what does still apply. But it means the machinery most readers picture — fair balance, the brief summary, the major statement, the agency that writes letters about them — is not what stands behind the page they are reading. Who does inspect the pharmacy behind it is the subject of the oversight article.
The one advertising ban that existed was struck down, then deleted
There used to be a federal statute directly on this. As enacted in 1997, section 503A conditioned the compounding exemption on silence: a drug could be compounded under the section “only if the pharmacy, licensed pharmacist, or licensed physician does not advertise or promote the compounding of any particular drug, class of drug, or type of drug,” though the compounding service could be advertised.[5]
In 2002 the Supreme Court held that provision unconstitutional. The decision in Thompson v. Western States Medical Center states the holding plainly: the Act’s “prohibitions on soliciting prescriptions for, and advertising, compounded drugs amount to unconstitutional restrictions on commercial speech,” because the government had not shown the restrictions were necessary rather than merely convenient. The opinion adds the line the case is remembered for: “If the First Amendment means anything, it means that regulating speech must be a last — not first — resort.”[6]
Eleven years later Congress finished the job. The Drug Quality and Security Act of 2013 struck the subsection out of the statute entirely and redesignated what followed it.[5] So the current text of 21 U.S.C. § 353a contains no advertising restriction of any kind, and has not since November 2013. The three federal requirements the section does switch off, and what that leaves in place, are covered in the 503A and 503B article.
The shape of that history is worth holding onto. The category with no premarket review of safety, efficacy or quality — compounded drugs are not FDA-approved and are not reviewed by the FDA before they are dispensed — is also the category whose one statutory speech restriction was removed on free-speech grounds. Less review and fewer drug-advertising rules arrived together.
What does apply, and it is not nothing
The Federal Trade Commission’s authority runs to advertising generally, and its December 2022 Health Products Compliance Guidance distills it to two principles: advertising must be truthful and not misleading, and “before disseminating an ad, advertisers must have adequate substantiation for all objective product claims conveyed, expressly or by implication, to consumers acting reasonably.” For health products the substantiation standard is “competent and reliable scientific evidence,” and the guidance states that as a general matter that will need to be “randomized, controlled human clinical testing.”[7]
Two features of that regime matter here more than they would anywhere else. First, the guidance says outright that “FTC law makes no bright-line distinctions between categories of health-related products or claims” — the standard that applies to a supplement, an approved drug and a compounded preparation is the same standard.[7] Second, its definition of advertising is deliberately wide, reaching packaging and labeling, brochures, websites and digital content, social media and influencer marketing, press releases and interviews, and promotion “indirectly through healthcare practitioners or other intermediaries.”[7]
The two agencies divide the territory by a 1971 memorandum of understanding. FDA has primary responsibility for claims in labeling — the package, product inserts, materials at point of sale — and FTC for claims in all forms of advertising, with the guidance adding that the agreement does not limit FTC’s jurisdiction or stop it acting on deceptive labeling claims.[7] And labeling is not exempt on the compounded side either: section 503A switches off three provisions, and section 502(a) — misbranded “if its labeling is false or misleading in any particular” — is not among them.[8] The statute also directs that in judging whether labeling or advertising is misleading, weight be given to “the extent to which the labeling or advertising fails to reveal facts material.”[9]
Which claims are not permitted
Four categories are identifiable from the published rules rather than from anyone’s opinion, and all four turn up in weight-loss marketing.
An approval that was not granted. FTC’s guidance warns that advertisers “should be careful not to mischaracterize the extent to which a product or claim has been reviewed, authorized, or approved by the FDA,” and its worked example is a device cleared for one narrow purpose whose infomercial repeated “FDA Approved” beside dramatic weight and waist claims — deceptive because the juxtaposition implied the agency had found the product effective for those effects.[7]
An effect borrowed from a different product’s trial. A claim about the benefits of the thing being sold needs evidence about the thing being sold. The guidance’s standard is that substantiation must be “relevant to the specific product and advertising claim”, and its examples show how a genuine study cited for a conclusion it did not support is deceptive even when the advertiser holds other evidence.[7]
A result presented without the conditions that produced it. In the guidance’s own supplement example, an ad quoting an average weight loss from a placebo-controlled trial should make clear that participants also cut calories and exercised, because users will need to do the same to see anything similar.[7] The published GLP-1 trials all ran alongside lifestyle intervention, which is why an arm mean lifted out of one is a claim about a protocol rather than a drug.
A testimonial standing in for evidence. Customer accounts, the guidance states, do not constitute substantiation; the advertiser must hold competent and reliable scientific evidence regardless, and a vague “results not typical” disclaimer does not fix a before-and-after photograph that conveys far more than the trial found.[7] Pricing claims have their own separate catalog of devices, set out in the price-advertising article.
What the research says about who gets advertised to
Direct-to-consumer promotion is not distributed in proportion to how much a drug adds. A cross-sectional analysis of the 150 top-selling branded prescription drugs in the United States in 2020 found a median 13.5% of promotional spending went to consumers rather than to clinicians (IQR 1.96% to 36.6%). Across the 134 drugs with complete data, the adjusted mean share allocated to consumer advertising was an absolute 14.3% higher for drugs rated as having low added clinical benefit than for those rated high (95% CI 1.43% to 27.2%; P = .03), and 1.5% higher for each 10% increase in total sales (95% CI 0.44% to 2.56%; P = .005).[10]
That is the direction most readers would not predict. The weaker the added benefit, the larger the share of the promotional budget pointed at the patient rather than the prescriber — consistent with consumer advertising being used where a clinical case is hardest to make. A 2026 review of the field puts manufacturer spending above $8 billion in 2023 and describes the ads as “tightly regulated in theory but less so in practice,” with recent encroachment into social media and telehealth, and few ads providing quantitative information on benefits and harms.[11] Both of those findings concern approved, branded drugs advertised by their manufacturers — the regulated case. They are the ceiling on what oversight achieves, not the floor.
How to read one
Three questions do most of the work. Does the page name what is being sold precisely enough to check — molecule, milligrams, route — or only a brand-shaped label? Does any number on it come from a trial of that preparation, or from a trial of an approved product that is not what will arrive? And is there a claim about approval, safety review or certification that a reader could mistake for a government finding? A missing state list or unnamed pharmacy belongs to a different checklist, in the red-flag article.
If something looks false or misleading, the routes are public. FDA takes reports of prescription drug promotion at BadAd@fda.gov or 855-RX-BADAD, and asks for the product name, the reason, and links or images of the material.[4] The FTC takes consumer complaints about advertising generally. Neither is a fast remedy, and FTC’s own guidance says its principles do not have the force of law and provide no safe harbor, because whether a particular claim is deceptive depends on the facts of the case.[7]
What could not be established
No published count of federal enforcement actions brought over the advertising of compounded GLP-1 preparations was located, and no such total is reported by OPDP — which follows from its published scope rather than from the absence of any conduct. No study comparing claim accuracy on compounded and approved GLP-1 marketing was found either. The statements here describe published rules and their sources; they do not assess any company, and nothing on this page is legal advice. The standards this site applies to its own claims are set out in the methodology.